Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alexander S. Farivar is active.

Publication


Featured researches published by Alexander S. Farivar.


The Annals of Thoracic Surgery | 2004

β-Chemokine function in experimental lung ischemia-reperfusion injury

Baiya Krishnadasan; Alexander S. Farivar; Babu V Naidu; Steven M. Woolley; Karen Byrne; Charles H. Fraga; Michael S. Mulligan

Abstract Background Although chemokines are functionally important in models of ischemia-reperfusion injury, little is known about their role in lung ischemia-reperfusion injury (LIRI). This study examined the role of the β-chemokines, macrophage inflammatory protein (MIP)-1α, monocyte chemoattractant protein (MCP)-1, and regulated upon activation normal T cells expressed and secreted (RANTES) in LIRI. Methods Left lungs of Long-Evans rats underwent normothermic ischemia for 90 minutes and reperfusion for up to 4 hours. Treated animals received anti–MIP-1α, anti–MCP-1, or anti-RANTES antibodies before reperfusion. Changes in lung vascular permeability were measured with iodine 125–labeled bovine serum albumin. Neutrophil accumulation in the lung parenchyma was determined by myeloperoxidase activity, and bronchoalveolar lavage was performed to measure leukocyte cell counts. Western blots, Northern blots, and ribonuclease protection assays assessed β-chemokine messenger RNA and protein levels. Results Animals receiving anti–MIP-1α demonstrated reduced vascular permeability compared with controls ( p p p p Conclusions MIP-1α is functionally significant in the development of LIRI. It likely exerts its effects in part by mediating the expression of proinflammatory and antiinflammatory cytokines and influencing tissue neutrophil recruitment. MCP-1 and RANTES seem to play relatively minor roles in the development of direct LIRI.


The Annals of Thoracic Surgery | 2003

Endogenous interleukin-4 and interleukin-10 regulate experimental lung ischemia reperfusion injury

Alexander S. Farivar; Baiya Krishnadasan; Babu V Naidu; Steven M. Woolley; Edward D. Verrier; Michael S. Mulligan

BACKGROUNDnRegulatory cytokines play functional roles in experimental heart, hindlimb, and liver ischemia reperfusion injury. However, little is known about their involvement in direct lung ischemia reperfusion injury (LIRI). These studies were undertaken to investigate the role of two regulatory cytokines, interleukin-4 (IL-4) and IL-10, in an in vivo model of LIRI.nnnMETHODSnLeft lungs of Long-Evans rats underwent normothermic ischemia for 90 minutes and reperfusion for up to 4 hours. Treated animals received either recombinant IL-4 or recombinant IL-10, or antibodies to IL-4 or IL-10 immediately before reperfusion. Lung injury was quantitated by permeability indices, lung parenchymal neutrophil sequestration (myeloperoxidase [MPO] content), and alveolar leukocyte content in bronchoalveolar lavage (BAL) effluent. Expression of IL-4 and IL-10 was determined by immunoblotting, and mRNA expression for early response cytokines was evaluated by ribonuclease protection assays.nnnRESULTSnIL-4 and IL-10 protein expression was significant after 2 hours of reperfusion. Animals receiving anti-IL-4 (p = 0.05) and anti-IL-10 (p = 0.01) antibodies demonstrated increased permeabilities compared with positive controls. Lung tissue neutrophil accumulation (p < 0.004) and BAL leukocyte content (p < 0.04) were also significantly increased in animals receiving anti-IL-10 antibodies. Conversely, animals receiving recombinant IL-4 and recombinant IL-10 demonstrated reduced permeabilities and lung MPO content. Both anti-IL-4 and anti-IL-10 treatment increased mRNA expression for a number of early response cytokines, including TNF-alpha and IL-1beta.nnnCONCLUSIONSnIL-4 and IL-10 are expressed in response to LIRI and function to decrease injury severity. These effects are partly due to modulated expression of early proinflammatory cytokines.


Experimental and Molecular Pathology | 2003

The role of the beta chemokines in experimental obliterative bronchiolitis.

Alexander S. Farivar; Baiya Krishnadasan; Babu V Naidu; Steven M. Woolley; Michael S. Mulligan

Beta chemokines have been implicated in cardiac and renal allograft rejection. This study determined if antibody antagonization of beta chemokines conferred protection against the development of experimental obliterative bronchiolitis (OB) in a heterotopic rat tracheal allograft model. Rat tracheas were transplanted from Brown-Norway or Lewis donors into Lewis recipients. Rats received 200 microg/day of either anti-RANTES or anti-MCP-1 antibody for 14 days. Luminal obstruction and epithelial loss were calculated. Northern blots for MCP-1 and RANTES mRNA expression were performed, and immunohistochemistry for chemokine protein localization. There was a significant increase in airway obstruction in allografts compared to isografts (P < 0.001). Antibody-treated allografts demonstrated an amelioration of airway obstruction from 58% (vehicle allografts) to 26% (anti-RANTES) and 12% (anti-MCP-1), both of which were significant (P < 0.001). Epithelial preservation was increased in both antibody-treated groups (P < 0.001), and increased expression of MCP-1 and RANTES mRNA was present in tracheal allografts by Day 2 and maximal by Day 6. Beta chemokines are expressed during the development of experimental OB, as MCP-1 and RANTES mRNA expression increased with time from transplantation. Both MCP-1 and RANTES are functional in the formation of the fibroproliferative response that characterizes OB in this model, and their antagonization conferred protection against airway obstruction and epithelial loss.


Journal of Heart and Lung Transplantation | 2004

Alpha chemokines regulate direct lung ischemia–reperfusion injury

Alexander S. Farivar; Baiya Krishnadasan; Babu V Naidu; Steven M. Woolley; Edward D. Verrier; Michael S. Mulligan

BACKGROUNDnAlpha chemokines function predominantly to recruit and activate neutrophils, which are important effectors of acute lung injury. This study evaluated whether blockade of 2 potent alpha chemokines, macrophage inflammatory protein-2 (MIP-2) and cytokine-induced neutrophil chemoattractant (CINC), is protective against lung ischemia-reperfusion injury in a warm in situ hilar clamp model.nnnMETHODSnLeft lungs of Long-Evans rats underwent normothermic ischemia for 90 minutes and reperfusion for up to 4 hours. Treated animals received antibodies to MIP-2 or CINC immediately prior to reperfusion. Lung injury was quantitated by vascular permeability to (125)I-radiolabeled bovine serum albumin, lung tissue neutrophil sequestration (myeloperoxidase [MPO] content), and alveolar leukocyte content in bronchoalveolar lavage (BAL) fluid. CINC and MIP-2 mRNA expression were assessed by northern blot, while ribonuclease protection assays were performed to evaluate mRNA expression for a number of early response cytokines. MIP-2 and CINC protein expression in injured lungs was determined by immunoblotting.nnnRESULTSnTreatment with antibodies to CINC or MIP-2 was associated with significant protection against increases in vascular permeability, MPO content and alveolar leukocyte sequestration in injured lungs. Expression of CINC and MIP-2 mRNA peaked after 2 hours of reperfusion in injured lungs, and protein levels were evident on immunoblotting after 3 hours of reperfusion. Neither CINC nor MIP-2 blockade appeared to modulate cytokine mRNA expression.nnnCONCLUSIONSnCINC and MIP-2 are important mediators involved in direct lung ischemia-reperfusion injury. They appear to function by modulating neutrophil recruitment, but not inflammatory cytokine release.


The Annals of Thoracic Surgery | 2008

Alveolar macrophage secretory products augment the response of rat pulmonary artery endothelial cells to hypoxia and reoxygenation.

Anton S. McCourtie; Heather E. Merry; Alexander S. Farivar; Christopher H. Goss; Michael S. Mulligan

BACKGROUNDnEndothelial cell activation is an important response to ischemia and reperfusion in a variety of vascular beds. Endothelial cells secrete a multitude of proinflammatory mediators and express adhesion molecules that promote leukocyte recruitment into injured tissues. Pulmonary artery endothelial cell response to lung ischemia-reperfusion injury does not appear robust enough to drive the development of lung injury independently. Rather, the alveolar macrophage is the key cell in the development of ischemia-reperfusion injury of the lung. Macrophages are known to be a rich source of inflammatory mediators, but the precise mechanism whereby they amplify injury is unknown. The aim of this study was to determine whether alveolar macrophage secretory products amplify the response of the endothelial cell using an in vitro model of lung reperfusion injury.nnnMETHODSnMacrophages were exposed to hypoxia and reoxygenation and the media collected. Cultured endothelial cells were then exposed to macrophage media and maintained at normoxia or subjected to hypoxia and reoxygenation. To assess any reciprocal effects of endothelial cell products on macrophage activation, macrophages were likewise exposed to activated endothelial cell media.nnnRESULTSnExposure of endothelial cells to activated alveolar macrophage media enhanced chemokine secretion in response to hypoxia and reoxygenation. In the reciprocal experiment, activated endothelial cell media increased the production of macrophage inflammatory protein 1alpha from macrophages.nnnCONCLUSIONSnAlveolar macrophages drive the development of lung reperfusion injury, by enhancing the production of proinflammatory chemokines from endothelial cells, which impart a degree of positive feedback on alveolar macrophages.


The Journal of Thoracic and Cardiovascular Surgery | 2004

Early tumor necrosis factor-α release from the pulmonary macrophage in lung ischemia-reperfusion injury

Babu V Naidu; Steven M. Woolley; Alexander S. Farivar; Robert Thomas; Charles H. Fraga; Christopher H. Goss; Michael S. Mulligan


Journal of Heart and Lung Transplantation | 2005

The Effect of Anti-inflammatory Properties of Mycophenolate Mofetil on the Development of Lung Reperfusion Injury

Alexander S. Farivar; Brendan Mackinnon-Patterson; Andrew D. Barnes; Michael S. Mulligan


The Annals of Thoracic Surgery | 2005

Cyclosporine Modulates the Response to Hypoxia-Reoxygenation in Pulmonary Artery Endothelial Cells

Alexander S. Farivar; Brendan Mackinnon-Patterson; Andrew D. Barnes; Anton S. McCourtie; Michael S. Mulligan


The Annals of Thoracic Surgery | 2005

Poly (ADP) Ribose Polymerase Inhibition Improves Rat Cardiac Allograft Survival

Alexander S. Farivar; Anton S. McCourtie; Brendan Mackinnon-Patterson; Steven M. Woolley; Andrew D. Barnes; Min Chen; Prakash Jagtap; Csaba Szabó; Christopher T. Salerno; Michael S. Mulligan


Journal of Surgical Research | 2003

Chemokine response of pulmonary artery endothelial cells to hypoxia and reoxygenation.

Babu V Naidu; Alexander S. Farivar; Steven M. Woolley; Karen Byrne; Michael S. Mulligan

Collaboration


Dive into the Alexander S. Farivar's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Steven M. Woolley

University of Washington Medical Center

View shared research outputs
Top Co-Authors

Avatar

Babu V Naidu

University of Washington Medical Center

View shared research outputs
Top Co-Authors

Avatar

Brendan Mackinnon-Patterson

University of Washington Medical Center

View shared research outputs
Top Co-Authors

Avatar

Anton S. McCourtie

University of Washington Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert Thomas

University of Washington Medical Center

View shared research outputs
Top Co-Authors

Avatar

Andrew D. Barnes

University of Washington Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge